Comparison of tocilizumab and high-dose methylprednisolone pulse on outcomes in severe corona virus disease-2019: TAME-COVID, a retrospective multicentric study

Background: India recently encountered fierce second wave of coronavirus disease (COVID-19), and scarcity of novel medications added to the management challenges. Various studies have highlighted the effectiveness of tocilizumab and high-dose steroids in severe COVIDs, but none has compared their ef...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of applied and basic medical research 2021-10, Vol.11 (4), p.263-269
Hauptverfasser: Kumar, Vipin, Kashyap, Anil, Kaur, Simran, John, Mary, Sibia, Raminderpal, Chopra, Vishal, Singla, Tanvi, Jindal, Jyoti, Sethi, Suman, Chhabra, Sandeep, Berry, Amit, Dhooria, Harmeet, Singh, Akashdeep, Garg, Vikas, Jain, Dinesh, Mahajan, Rajesh, Gautam, Parshotam, Midha, Vandana, Mohan, Bishav
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background: India recently encountered fierce second wave of coronavirus disease (COVID-19), and scarcity of novel medications added to the management challenges. Various studies have highlighted the effectiveness of tocilizumab and high-dose steroids in severe COVIDs, but none has compared their efficacy. Materials and Methods: This retrospective multi-centric analysis compares intravenous tocilizumab (8 mg/kg/day, maximum dose-800 mg), and intravenous Methylprednisolone Pulse (MPS-1 g/day for 3 days) in severe COVID-19. Both the groups had additionally received the standard of care COVID treatment as per protocol. Outcomes were assessed at 30 days. Results: A total of 336 patients, with 249 receiving MPS and 87 receiving tocilizumab were compared. Majority of these were males (72.9%) with a mean age of 57.4 ± 13.6 years. Diabetes was the most common comorbidity. Patients in both groups had comparable age distribution, comorbidities, presenting mean-arterial pressures, d-Dimer levels, serum ferritin, serum leukocyte-dehydrogenase, and procalcitonin. However, the tocilizumab group had more number of males, higher incidence of coronary artery disease, more tachypnea and leukocytosis, more number of patients with severe acute respiratory disease syndrome (PaO2/FiO2 ratio
ISSN:2229-516X
2248-9606
DOI:10.4103/ijabmr.ijabmr_448_21